These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 22176205)

  • 1. Protective hepatitis B surface antibodies in blood and ascites fluid in the early stage after liver transplantation for hepatitis B diseases.
    Wang K; Zhu ZJ; Zheng H; Deng YL; Pan C; Sun LY; Shen ZY
    Hepatol Res; 2012 Mar; 42(3):280-7. PubMed ID: 22176205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrence-free long-term survival after liver transplantation for hepatitis B using interferon-alpha pretransplant and hepatitis B immune globulin posttransplant.
    Tchervenkov JI; Tector AJ; Barkun JS; Sherker A; Forbes CD; Elias N; Cantarovich M; Cleland P; Metrakos P; Meakins JL
    Ann Surg; 1997 Sep; 226(3):356-65; discussion 365-8. PubMed ID: 9339942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis B immunoglobulin prophylaxis after liver transplantation: experience in a tertiary transplant centre.
    Varghese J; Sachan D; Reddy MS; Cherian T; Jothimani D; Venugopal K; Arikichenin O; Perumalla R; Narasimhan G; Shanmugam V; Vijaya S; Venkataraman J; Rela M
    J Clin Exp Hepatol; 2014 Sep; 4(3):209-13. PubMed ID: 25755562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimization of anti-hepatitis B surface antigen immunoglobulins for prophylaxis of hepatitis B viral recurrence in the first month after liver transplantation: the meaning of HBsAg quantitative level at the time of transplant.
    Tandoi F; Nada E; Pittaluga F; Fop F; Lupo F; Romagnoli R; Salizzoni M
    Transplant Proc; 2014 Sep; 46(7):2308-11. PubMed ID: 25242775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease.
    Dickson RC; Terrault NA; Ishitani M; Reddy KR; Sheiner P; Luketic V; Soldevila-Pico C; Fried M; Jensen D; Brown RS; Horwith G; Brundage R; Lok A
    Liver Transpl; 2006 Jan; 12(1):124-33. PubMed ID: 16382463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of hepatitis B immunization on prevention of mother-to-infant transmission of hepatitis B virus and on the immune response of infants towards hepatitis B vaccine.
    Zhang L; Gui XE; Teter C; Zhong H; Pang Z; Ding L; Li F; Zhou Y; Zhang L
    Vaccine; 2014 Oct; 32(46):6091-7. PubMed ID: 25240752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration.
    Rosenau J; Kreutz T; Kujawa M; Bahr MJ; Rifai K; Hooman N; Finger A; Michel G; Nashan B; Kuse ER; Klempnauer J; Tillmann HL; Manns MP
    J Hepatol; 2007 Apr; 46(4):635-44. PubMed ID: 17316869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete hepatitis B virus prophylaxis withdrawal in hepatitis B surface antigen-positive liver transplant recipients after longterm minimal immunosuppression.
    Lenci I; Baiocchi L; Tariciotti L; Di Paolo D; Milana M; Santopaolo F; Manzia TM; Toti L; Svicher V; Tisone G; Perno CF; Angelico M
    Liver Transpl; 2016 Sep; 22(9):1205-13. PubMed ID: 27272189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B recurrence after liver transplantation: a single center experiences and review the literature.
    Dehghani SM; Taghavi SA; Geramizadeh B; Nikeghbalian S; Derakhshan N; Malekpour A; Malek-Hosseini SA
    Hepat Mon; 2013 Jan; 13(1):e6609. PubMed ID: 23483668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active immunization for prevention of De novo hepatitis B virus infection after adult living donor liver transplantation with a hepatitis B core antigen-positive graft.
    Wang SH; Loh PY; Lin TL; Lin LM; Li WF; Lin YH; Lin CC; Chen CL
    Liver Transpl; 2017 Oct; 23(10):1266-1272. PubMed ID: 28691231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active immunization in patients transplanted for hepatitis B virus related liver diseases: A prospective study.
    Yang A; Guo Z; Ren Q; Wu L; Ma Y; Hu A; Wang D; Ye H; Zhu X; Ju W; He X
    PLoS One; 2017; 12(11):e0188190. PubMed ID: 29145470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients.
    Stärkel P; Stoffel M; Lerut J; Horsmans Y
    Liver Transpl; 2005 Oct; 11(10):1228-34. PubMed ID: 16184571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose hepatitis B immune globulin and higher-dose lamivudine combination to prevent hepatitis B virus recurrence after liver transplantation.
    Karasu Z; Ozacar T; Akyildiz M; Demirbas T; Arikan C; Kobat A; Akarca U; Ersoz G; Gunsar F; Batur Y; Kilic M; Tokat Y
    Antivir Ther; 2004 Dec; 9(6):921-7. PubMed ID: 15651751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effective and safe ambulatory long-term immunoprophylaxis with intramuscular instead of intravenous hepatitis B immunoglobulin to prevent reinfection after orthotopic liver transplantation.
    Faust D; Rabenau HF; Allwinn R; Caspary WF; Zeuzem S
    Clin Transplant; 2003 Jun; 17(3):254-8. PubMed ID: 12780677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Passive immunization of chronic hepatitis B patients on lamivudine therapy: a feasible issue?
    van Nunen AB; de Man RA; Heijtink RA; Vossen AC; Schalm SW
    J Viral Hepat; 2002 May; 9(3):221-8. PubMed ID: 12010511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prevention and treatment of hepatitis B virus reinfection after liver transplantation].
    Liu J; Wu GC; Zhang ZT; Wu P; Zhang D; Sun MC; Gao DC; Wang Y; Jia JD; Wang BE
    Zhonghua Wai Ke Za Zhi; 2005 Aug; 43(15):976-9. PubMed ID: 16194352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization.
    McGory RW; Ishitani MB; Oliveira WM; Stevenson WC; McCullough CS; Dickson RC; Caldwell SH; Pruett TL
    Transplantation; 1996 May; 61(9):1358-64. PubMed ID: 8629297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective.
    Wesdorp DJ; Knoester M; Braat AE; Coenraad MJ; Vossen AC; Claas EC; van Hoek B
    J Clin Virol; 2013 Sep; 58(1):67-73. PubMed ID: 23880162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin.
    Terrault NA; Zhou S; Combs C; Hahn JA; Lake JR; Roberts JP; Ascher NL; Wright TL
    Hepatology; 1996 Dec; 24(6):1327-33. PubMed ID: 8938155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B virus infection in heart transplant recipients in a hepatitis B endemic area.
    Ko WJ; Chou NK; Hsu RB; Chen YS; Wang SS; Chu SH; Lai MY
    J Heart Lung Transplant; 2001 Aug; 20(8):865-75. PubMed ID: 11502409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.